Val66Met polymorphism association with serum BDNF and inflammatory biomarkers in major depression

References

• Amorim P. 2000. Mini International Neuropsychiatric Interview (MINI): validation of a short structured diagnostic psychiatric interview. Rev Bras Psiquiatr. 22:106–115.
   Google Scholar
• Anisman H, Hayley S. 2012. Inflammatory factors contribute to depression and its comorbid conditions. Sci Signal. 5:pe45–pe45.
   PubMed Web of Science ®Google Scholar
• Audet M-C, Anisman H. 2013. Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses. Front Cell Neurosci. 7:68.
   PubMed Web of Science ®Google Scholar
• Autry AE, Monteggia LM. 2012. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 64:238–258.
   PubMed Web of Science ®Google Scholar
• Bus BAA, Arias-Vasquez A, Franke B, Prickaerts J, de Graaf J, Voshaar RCO. 2012. Increase in serum brain-derived neurotrophic factor in met allele carriers of the BDNF Val66Met polymorphism is specific to males. Neuropsychobiology. 65:183–187.
   PubMed Web of Science ®Google Scholar
• Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. 2014. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci. 8:430.
   PubMed Web of Science ®Google Scholar
• Cassano P, Bui E, Rogers AH, Walton ZE, Ross R, Zeng M, Nadal-Vicens M, Mischoulon D, Baker AW, Keshaviah A, et al. 2017. Inflammatory cytokines in major depressive disorder: a case-control study. Aust N Z J Psychiatry. 51:23–31.
   PubMed Web of Science ®Google Scholar
• Chen Z-Y, Bath K, McEwen B, Hempstead B, Lee F. 2008. Impact of genetic variant BDNF (Val66Met) on brain structure and function. Novartis Found Symp. 289:180–188. Discussion 188–195.
   PubMedGoogle Scholar
• Dooley LN, Ganz PA, Cole SW, Crespi CM, Bower JE. 2016. Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. J Affect Disord. 197:43–50.
   PubMed Web of Science ®Google Scholar
• Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. 2010. A meta-analysis of cytokines in major depression. Biol Psychiatry. 67:446–457.
   PubMed Web of Science ®Google Scholar
• D’Sa C, Duman RS. 2002. Antidepressants and neuroplasticity. Bipolar Disord. 4:183–194.
   PubMed Web of Science ®Google Scholar
• Duman RS. 2014. Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci. 16:11–27.
   PubMed Web of Science ®Google Scholar
• Duman RS, Aghajanian GK. 2012. Synaptic dysfunction in depression: potential therapeutic targets. Science. 338:68–72.
   PubMed Web of Science ®Google Scholar
• Duman RS, Malberg J, Nakagawa S, D’Sa C. 2000. Neuronal plasticity and survival in mood disorders. Biol. Psychiatry. 48:732–739.
   PubMed Web of Science ®Google Scholar
• Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, et al. 2003. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 112:257–269.
   PubMed Web of Science ®Google Scholar
• Elzinga BM, Molendijk ML, Oude Voshaar RC, Bus BAA, Prickaerts J, Spinhoven P, Penninx BJWH. 2011. The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met. Psychopharmacology (Berl). 214:319–328.
   PubMed Web of Science ®Google Scholar
• Gawali NB, Bulani VD, Chowdhury AA, Deshpande PS, Nagmoti DM, Juvekar AR. 2016. Agmatine ameliorates lipopolysaccharide induced depressive-like behaviour in mice by targeting the underlying inflammatory and oxido-nitrosative mediators. Pharmacol Biochem Behav. 149:1–8.
   PubMed Web of Science ®Google Scholar
• Ge L, Liu L, Liu H, Liu S, Xue H, Wang X, Yuan L, Wang Z, Liu D. 2015. Resveratrol abrogates lipopolysaccharide-induced depressive-like behavior, neuroinflammatory response, and CREB/BDNF signaling in mice. Eur J Pharmacol. 768:49–57.
   PubMed Web of Science ®Google Scholar
• Gibney SM, McGuinness B, Prendergast C, Harkin A, Connor TJ. 2013. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun. 28:170–181.
   PubMed Web of Science ®Google Scholar
• González-Giraldo Y, Camargo A, López-León S, Forero DA. 2015. No association of BDNF, COMT, MAOA, SLC6A3, and SLC6A4 genes and depressive symptoms in a sample of healthy colombian subjects. Depress Res Treat. 2015:145483.
   PubMedGoogle Scholar
• Grande I, Magalhães PVS, Chendo I, Stertz L, Fries GR, Cereser KM, Cunha ÂBM, Gói P, Kunz M, Udina M, et al. 2014. Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: an open-label trial. Acta Psychiatr Scand. 129:393–400.
   PubMed Web of Science ®Google Scholar
• Groves JO. 2007. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry. 12:1079–1088.
   PubMed Web of Science ®Google Scholar
• Guan Z, Fang J. 2006. Peripheral immune activation by lipopolysaccharide decreases neurotrophins in the cortex and hippocampus in rats. Brain Behav Immun. 20:64–71.
   PubMed Web of Science ®Google Scholar
• Guo J, Lin P, Zhao X, Zhang J, Wei X, Wang Q, Wang C. 2014. Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice. Neuroscience. 263:1–14.
   PubMed Web of Science ®Google Scholar
• Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. 2015. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 49:206–215.
   PubMed Web of Science ®Google Scholar
• Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 6:278–296.
   PubMed Web of Science ®Google Scholar
• Hosang GM, Shiles C, Tansey KE, McGuffin P, Uher R. 2014. Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis. BMC Med. 12:7.
   PubMed Web of Science ®Google Scholar
• Jamal M, Van der Does W, Elzinga BM, Molendijk ML, Penninx BWJH. 2015. Association between smoking, nicotine dependence, and BDNF Val66Met polymorphism with BDNF concentrations in serum. Nicotine Tob Res. 17:323–329.
   PubMed Web of Science ®Google Scholar
• Kenis G, Prickaerts J, van Os J, Koek GH, Robaeys G, Steinbusch HWM, Wichers M. 2011. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor? Int J Neuropsychopharmacol. 14:247–253.
   PubMed Web of Science ®Google Scholar
• Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, et al. 2017. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatrica Scandinavica. 135:373–387.
   PubMed Web of Science ®Google Scholar
• Lang UE, Hellweg R, Sander T, Gallinat J. 2009. The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry. 14:120–122.
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Araujo DM, Hefti F. 1993. Systemic interleukin-1 beta decreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation. Neuroscience. 53:297–301.
   PubMed Web of Science ®Google Scholar
• Linn BS, Linn MW, Gurel L. 1968. Cumulative illness rating scale. J Am Geriatr Soc. 16:622–626.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ho RC-M, Mak A. 2012. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 139:230–239.
   PubMed Web of Science ®Google Scholar
• Lotrich FE, Albusaysi S, Ferrell RE. 2013. Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment. Neuropsychopharmacology. 38:985–995.
   PubMed Web of Science ®Google Scholar
• Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, Ruberto A, Tatarelli R, Nicoletti F, Girardi P, et al. 2009. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res. 43:247–254.
   PubMed Web of Science ®Google Scholar
• Miller AH, Raison CL. 2016. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 16:22–34.
   PubMed Web of Science ®Google Scholar
• Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF. 1992. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 41:237–248.
   PubMed Web of Science ®Google Scholar
• Molendijk ML, Bus BAA, Spinhoven P, Penninx BWJH, Kenis G, Prickaerts J, Voshaar RCO, Elzinga BM. 2011. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry. 16:1088–1095.
   PubMed Web of Science ®Google Scholar
• Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BWJH, Elzinga BM. 2014. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry. 19:791–800.
   PubMed Web of Science ®Google Scholar
• Moreira FP, Fabião JD, Bittencourt G, Wiener CD, Jansen K, Oses JP, Quevedo L, de Á, Souza LDM, Crispim D, Portela LV, et al. 2015. The Met allele of BDNF Val66Met polymorphism is associated with increased BDNF levels in generalized anxiety disorder. Psychiatr Genet. 25:201–207.
   PubMed Web of Science ®Google Scholar
• Neto FL, Borges G, Torres-Sanchez S, Mico JA, Berrocoso E. 2011. Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Curr Neuropharmacol. 9:530–552.
   PubMed Web of Science ®Google Scholar
• Numakawa T, Richards M, Nakajima S, Adachi N, Furuta M, Odaka H, Kunugi H. 2014. The role of brain-derived neurotrophic factor in comorbid depression: possible linkage with steroid hormones, cytokines, and nutrition. Front Psychiatry. 5:136.
   PubMed Web of Science ®Google Scholar
• Ozan E, Okur H, Eker Ç, Eker ÖD, Gönül AS, Akarsu N. 2010. The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels. Brain Res Bull. 81:61–65.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, Pi B, Thurmond L, Bilello JA. 2013. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol. Psychiatry. 18:332–339.
   PubMed Web of Science ®Google Scholar
• Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SDJ. 2003. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA. 100:177–182.
   PubMed Web of Science ®Google Scholar
• Patas K, Penninx BWJH, Bus BAA, Vogelzangs N, Molendijk ML, Elzinga BM, Bosker FJ, Oude Voshaar RC. 2014. Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features. Brain Behav Immun. 36:71–79.
   PubMed Web of Science ®Google Scholar
• Pivac N, Kim B, Nedić G, Joo YH, Kozarić-Kovacić D, Hong JP, Muck-Seler D. 2009. Ethnic differences in brain-derived neurotrophic factor Val66Met polymorphism in Croatian and Korean healthy participants. Croat Med J. 50:43–48.
   PubMed Web of Science ®Google Scholar
• Ribeiro L, Busnello JV, Cantor RM, Whelan F, Whittaker P, Deloukas P, Wong M-L, Licinio J. 2007. The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. Neuroreport. 18:1291–1293.
   PubMed Web of Science ®Google Scholar
• Şahin TD, Karson A, Balcı F, Yazır Y, Bayramgürler D, Utkan T. 2015. TNF-alpha inhibition prevents cognitive decline and maintains hippocampal BDNF levels in the unpredictable chronic mild stress rat model of depression. Behav Brain Res. 292:233–240.
   PubMed Web of Science ®Google Scholar
• Sánchez-Mora C, Ribasés M, Ramos-Quiroga JA, Casas M, Bosch R, Boreatti-Hümmer A, Heine M, Jacob CP, Lesch K-P, Fasmer OB, et al. 2010. Meta-analysis of brain-derived neurotrophic factor p.Val66Met in adult ADHD in four European populations. Am J Med Genet B Neuropsychiatr Genet. 153B:512–523.
   PubMed Web of Science ®Google Scholar
• Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, Schulze TG, Deschner M, Schmäl C, Höfels S, et al. 2005. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry. 58:307–314.
   PubMed Web of Science ®Google Scholar
• Sen S, Duman R, Sanacora G. 2008. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 64:527–532.
   PubMed Web of Science ®Google Scholar
• Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. 2001. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29:308–311.
   PubMed Web of Science ®Google Scholar
• Spanemberg L, Caldieraro M, Arrua Vares E, Wollenhaupt de Aguiar B, Yuri Kawamoto S, Parker G, Pio Fleck M, Kauer-Sant’Anna M, Galvao E. 2014. Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure. Neuropsychiatr Dis Treat. 10:1523–1531.
   PubMed Web of Science ®Google Scholar
• Surtees PG, Wainwright NWJ, Willis-Owen SAG, Sandhu MS, Luben R, Day NE, Flint J. 2007. No association between the BDNF Val66Met polymorphism and mood status in a non-clinical community sample of 7389 older adults. J Psychiatr Res. 41:404–409.
   PubMed Web of Science ®Google Scholar
• Terracciano A, Piras MG, Lobina M, Mulas A, Meirelles O, Sutin AR, Chan W, Sanna S, Uda M, Crisponi L, et al. 2013. Genetics of serum BDNF: meta-analysis of the Val66Met and genome-wide association study. World J Biol Psychiatry. 14:583–589.
   PubMed Web of Science ®Google Scholar
• Tramontina J, Frey BN, Andreazza AC, Zandona M, Santin A, Kapczinski F. 2007. Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Mol Psychiatry. 12:230–231.
   PubMed Web of Science ®Google Scholar
• Verhagen M, van der Meij A, van Deurzen PAM, Janzing JGE, Arias-Vásquez A, Buitelaar JK, Franke B. 2010. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry. 15:260–271.
   PubMed Web of Science ®Google Scholar
• Vinberg M, Bukh JD, Bennike B, Kessing LV. 2013. Are variations in whole blood BDNF level associated with the BDNF Val66Met polymorphism in patients with first episode depression? Psychiatry Res. 210:102–108.
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J. 2009. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry. 33:722–726.
   PubMed Web of Science ®Google Scholar
• Zhang J-C, Yao W, Hashimoto K. 2016. Brain-derived Neurotrophic Factor (BDNF)-TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol. 14:721–731.
   PubMed Web of Science ®Google Scholar
• Zhang K, Yang C, Xu Y, Sun N, Yang H, Liu J, Xu Q, Shen Y. 2010. Genetic association of the interaction between the BDNF and GSK3B genes and major depressive disorder in a Chinese population. J Neural Transm (Vienna). 117:393–401.
   PubMed Web of Science ®Google Scholar
• Zhang J-C, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li S-X, Shirayama Y, Hashimoto K. 2015. Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharm. 18:pyu077–7.
   Web of Science ®Google Scholar
• Zhu L, Nang C, Luo F, Pan H, Zhang K, Liu J, Zhou R, Gao J, Chang X, He H, et al. 2016. Esculetin attenuates lipopolysaccharide (LPS)-induced neuroinflammatory processes and depressive-like behavior in mice. Physiol Behav. 163:184–192.
   PubMed Web of Science ®Google Scholar